Overview

First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors

Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Axitinib